Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab - Lin, S; Kennedy, NA; Saifuddin, A (Nat Commun, 2022)
et al.